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A B S T R A C T
Epidemiological studies suggest an inverse correlation between dietary calcium (Ca2+) and vitamin D
intake and the risk of colorectal cancer (CRC). It has been shown in vitro that the active vitamin D
metabolite, 1,25-dihydroxyvitamin D3 (1,25-D3) can upregulate expression of the calcium-sensing
receptor (CaSR). In the colon, CaSR has been suggested to regulate proliferation of colonocytes. However,
during tumorigenesis colonic CaSR expression is downregulated and we hypothesized that the loss of
CaSR could inﬂuence the anti-tumorigenic effects of Ca2+ and vitamin D. Our aim was to assess the impact
of CaSR expression and function on the anti-neoplastic effects of 1,25-D3 in colon cancer cell lines.
We demonstrated that in the healthy colon of mice, high vitamin D diet (2500 IU/kg diet) increased
expression of differentiation and apoptosis markers, decreased expression of proliferation markers and
signiﬁcantly upregulated CaSR mRNA expression, compared with low vitamin D diet (100 IU/kg diet). To
determine the role of CaSR in this process, we transfected Caco2-15 and HT29 CRC cells with wild type
CaSR (CaSR-WT) or a dominant negative CaSR mutant (CaSR-DN) and treated them with 1,25-D3 alone, or
in combination with CaSR activators (Ca2+ and NPS R-568).1,25-D3 enhanced the anti-proliferative effects
of Ca2+ and induced differentiation and apoptosis only in cells with a functional CaSR, which were further
enhanced in the presence of NPS R-568, a positive allosteric modulator of CaSR. The mutant CaSR
inhibited the anti-tumorigenic effects of 1,25-D3 suggesting that the anti-neoplastic effects of 1,25-D3
are, at least in part, mediated by the CaSR.
Taken together, our data provides molecular evidence to support the epidemiological observation that
both, vitamin D and calcium are needed for protection against malignant transformation of the colon and
that their effect is modulated by the presence of a functional CaSR.
This article is part of a Special Issue entitled ‘17th Vitamin D Workshop’.
ã 2015 Z. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Colorectal cancer (CRC), the third leading cause of death from
cancer worldwide [1] is a slowly developing disease. Dietary
inﬂuences account for 70–90% of CRC development, making it
preventable to a great extent. Experimental, epidemiological and
clinical studies, although not consistent, suggest an inverse
correlation between calcium and vitamin D intake and risk for
CRC [2,3]. The Second Expert Report [4] by the World Cancer
Research Fund and the American Institute for Cancer Research
suggests that calcium is a factor that ‘probably’ decreases risk for
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CRC development, whereas the effects of vitamin D are ‘limited-
suggestive’.
Deregulation of the dynamic balance between proliferation,
differentiation, and apoptosis represents a risk for development of
colonic tumors [5]. Although animal studies suggest that calcium
and vitamin D regulate these anti-neoplastic processes in the colon
[6–8], clinical studies are inconsistent. This has led to a shifted
focus toward combinational chemoprevention studies, which
propose the existence of a cross talk between calcium and vitamin
D signaling in protection against CRC. In a randomized, placebo-
controlled clinical trial, Grau et al. [9] showed that only a combined
supplementation of calcium and vitamin D could reduce risk of
colorectal cancer. In addition, Holt et al. [10] were able to
demonstrate reduced polyp formation in adenoma patients
receiving calcium and vitamin D supplementation together. In
another study, Fedirko et al. [11] described that high dietary
calcium intake (928 mg/d) and increased circulating 25-hydrox-
yvitamin D levels correlated with reduced CRC-related mortality.
These studies call for a clearer understanding of the molecular
mechanisms behind the cross talk between the vitamin D system
and calcium signaling that could regulate anti-neoplastic effects in
the colon.
Dietary vitamin D3 is hydroxylated in the liver at carbon-25 by
the vitamin D 25-hydroxylases CYP2R1 and CYP27A1 to form the
precursor, 25-hydroxyvitamin D3 (25-D3). 25-D3 bound to vitamin
D binding protein (DBP) is delivered to the kidney where an
additional hydroxylation step at carbon-1 by 25-D3 1a-hydroxy-
lase (CYP27B1) converts it to the biologically active form of vitamin
D, 1,25-dihydroxyvitamin D3 (1,25-D3). Besides the kidney, several
other extra-renal tissues, including the intestine, are able to
synthesize and degrade 1,25-D3 locally [12].
The calcium-sensing receptor (CaSR) is a G-protein coupled
receptor, and its promoter harbors two vitamin D response
elements (VDRE) [13]. Thus, 1,25-D3 is able to upregulate the
expression of the CaSR [14,15]. In addition to its key role in
regulating calcium homeostasis, the CaSR is involved in processes
controlling cell growth in several tissues [16] as evidenced e.g.,
in the colon of CaSR knock out mice that have hyperproliferative
colonic crypts with increased susceptibility to form aberrant crypt
foci [17–19]. During colorectal tumorigenesis, expression of the
CaSR is lost in late-stage, undifferentiated tumors [20,21]. On the
basis of these observations, we hypothesize that the CaSR is
one of the key molecules linking the anti-neoplastic effects of
calcium and vitamin D. Therefore the present study evaluated
whether the expression level and functionality of the CaSR
inﬂuences vitamin D signaling thereby potentiating the effects of
calcium in the colon.
2. Materials and methods
2.1. In vivo study – animals, diet and xenograft establishment
6-weeks-old male C.B-17/IcrHan1Hsd-Prkdcscid mice were
purchased from Harlan Laboratories and housed at the Institute
of Cancer Research at the Medical University of Vienna in a
controlled environment in accordance with the European Union
Regulations on Care and Use of Laboratory Animals. The study was
approved by the Ethics Committee of the Medical University of
Vienna (Nr. BMWF-66.009/0115-II/3b/2013). Upon arrival, animals
were divided into two diet groups (5 mice/group) and received a
modiﬁed AIN-93G diet containing either 100 IU vitamin D3/kg diet
(low vitamin D diet) or 2500 IU vitamin D3/kg diet (high vitamin D
diet) (Ssniff Special Diet, Germany). After 2-weeks of acclimatiza-
tion, HT29 cells (1 106) were inoculated in the left ﬂank of the
animals and xenograft growth was monitored for 3 weeks. Tumor
volume was calculated using the formula (length  width2/2). At
the end of the study, mice were euthanized by cervical dislocation
(Fig. 1A). The colon was collected and washed in ice-cold PBS.
A small portion of the ascending colon and the tumor tissue was
immediately snap frozen in liquid nitrogen. The majority of
the colonic tissue was ﬁxed in 4% buffered formalin and rolled
into a plane spiral (Swiss roll), dehydrated and embedded in
parafﬁn.
2.2. Immunohistochemistry
4 mm sections were cut and stained for Ki67 (1:400, Novus
Biologicals, USA) on a Ventana Discovery XT autostainer (Ventana,
USA) using cell conditioner 1 as pre-treatment, rabbit OmniMap
(Ventana) as detection system, and Hematoxylin (DAKO, Austria)
as counter stain. Whole section images were acquired using the
automated TissueFAXS system (TissueGnostics, Austria). At least
10 intact crypts per colon were identiﬁed and the percentage of
Ki67-positive cells per crypt (in both, ascending and descending
colon) was quantiﬁed in a blinded fashion.
2.3. Cell culture
Moderately differentiated HT29, and well-differentiated Caco2-
15 (a sub-clone of the Caco2 cell line [22]) colon cancer cell lines
were used in this study. Cells were tested for their authenticity at
the DNA Diagnostic Center (UK). LipofectamineTM LTX (Life
Technologies, Austria) was used to transfect the cells with
pcDNA3.1/Zeo plasmid (Life Technologies) containing either a full
length, wild type cDNA of the CaSR (CaSR-WT), or a construct
harboring a dominant negative inactivating mutation (R185Q) of
the CaSR (CaSR-DN). The pcDNA3.1/Zeo vector was used as a
control (EMPTY). Zeocin was the antibiotic of choice, given that it
does not inﬂuence CaSR function. Stable cell lines were generated
by selecting Zeocin resistant clones for over 6 months in culture.
All cells were routinely cultured in Dulbecco’s Modiﬁed Eagle
Medium (DMEM) which contains 1.8 mM Ca2+, supplemented with
10% FBS, 10 mM Hepes, 2 mM L-glutamine, 100 U/ml penicillin/
streptomycin (all Life Technologies) in a 5% CO2/humidiﬁed air
incubator, maintained at 37 C. Media of transfected cells was
supplemented with 150 mg/ml (HT29) or 75 mg/ml (Caco2-15)
Zeocin (Life Technologies). Mycoplasma detection tests were
routinely performed using VenorGem Mycoplasma Detection Kit
(Minerva Biolabs, Germany).
2.4. Functional assays
One week post conﬂuence, the culture medium was changed to
calcium-free DMEM (Life Technologies) and the cells were exposed
to either Ca2+ (1.8 mM, Sigma, Germany), 1,25-D3 (1 nM in ethanol,
Sigma) or a combination of Ca2+ and 1,25-D3 for 48 h. To conﬁrm
the role of CaSR, cells were pre-treated with a positive allosteric
modulator of CaSR, NPS R-568 (1 mM in DMSO) for 10 min before
exposing them to 1.8 mM Ca2+ alone or a combination of 1.8 mM
Ca2+ and 1 nM 1,25-D3 for 48 h. Vehicle treated cells were used as
controls.
Proliferation was measured by counting viable cells after
detaching them with trypsin using the T10 Automated cell counter
(BioRad, USA). Differentiation was determined using the Alkaline
Phosphatase (ALP) Colorimetric Assay Kit (Abcam, UK). ALP activity
per 105 cells was calculated and data presented in units/ml.
Apoptosis was evaluated using the Apo-ONE Homogeneous
Caspase 3/7 Assay Kit (Promega, Germany) and data were
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normalized to the number of viable cells. All experiments were
performed at least in biological triplicates according to the
manufacturer’s instructions.
2.5. RNA isolation, reverse transcription and real time qRT-PCR
Snap frozen tissue was homogenized in TRIzol (Life Technolo-
gies, USA) using the Precellys 24-Dual Homogenizer (Precellys,
France). RNA isolation and cDNA reverse transcription were
performed as previously described [23]. Real time qRT-PCR
analysis was performed on the Step One Plus using Power SYBR
Green system (Life Technologies) and gene expression calculated
based on the 2DDCt method and set relative to a total RNA
calibrator (Clontech, USA). Primers used were: mouse Cyclin D1
(Fwd: GAACAAGCTCAAGTGGAAC; Rev: GAACTTCACATCTGTGGCA),
mouse Sucrase Isomaltase (mSI) (Fwd: ACAGCAAGCCGAAAGAATCC;
Rev: TTCACCATCATCCCAGAAGAG), mouse B-cell lymphoma 2
(mBCL-2) (Fwd: CATGTGTGTGGAGAGCGTCAA; Rev:
GCCGGTTCAGGTACTCAGTCA), mouse Bcl-2 associated X protein
(mBAX) (Fwd: TGGAGCTGCAGAGGATGATTG; Rev: GAAAACATGT-
CAGCTGCCACTC) and mouse calcium-sensing receptor (mCaSR)
(Fwd: GAGGCCTGGCAGGTCCTGAA; Rev: TGATGGAGTAGTTCCC-
CACC). Mouse intestinal Alkaline Phosphatase (mALP) mRNA levels
were detected using the TaqMan gene expression system
(Mm01285814_g1, Life Technologies). Data were normalized to
the expression of the housekeeping gene, mouse eukaryotic
translation elongation factor 1 beta 2 (mEEF1B2) (Fwd: AGAGCTA-
CATTGAGGGGTACG; Rev: GACTTGATGTGATTATACCAACGTAG). For
gene expression in the human xenografts, primers used for CaSR
expression analysis and housekeeping genes, human beta-2
microglobulin (hß2M), human glutaminyl-tRNA synthetase (hQARS)
and human large ribosomal protein (hRPLP0) have been previously
published [14,24].
2.6. Statistical analysis
All statistical analyses were performed using SPSS (IBM, USA)
and graphs plotted using GraphPad Prism (GraphPad Software Inc.
USA). Non-normally distributed data was log-transformed to
achieve normal distribution. Unpaired t-test was used to compare
between the two animal groups after Grubbs outlier test was
performed using GraphPad Prism. Statistically signiﬁcant outliers
were excluded from analysis. For analysis of the 2  2 factorial-
designed functional experiments, we used two-way ANOVA
followed by Tukey’s multiple correction. For analysis of the groups
treated with or without the Calcimimetic (NPS R-568), we used
one-way ANOVA followed by Tukey’s multiple correction. P-values
less than 0.05 were considered statistically signiﬁcant.
Fig.1. Effect of dietary vitamin D on tumor xenograft and mouse colon. Schematic representation of in vivo study. Upon arrival, mice were fed normal AIN-93G diet for 1 week,
after which mice were randomly distributed into two groups receiving either a diet containing high vitamin D (2500 IU/kg diet) or low vitamin D (100 IU/kg diet). After
2 weeks of diet acclimatization, mice were injected with HT29 cells to establish tumor xenografts and fed their respective diets. At the end of the study mice were euthanized
by cervical dislocation (A). We measured volume of the HT29 xenografts (B), CaSR mRNA expression in the xenografts (C), and CaSR mRNA expression in the mouse colon (D).
Median, interquartile range and whiskers (min and max) are shown. Statistical signiﬁcance was calculated using unpaired t-test. n = 5 animals per group except C where we
identiﬁed one signiﬁcant outlier in both groups (using Grubbs test) and these were excluded from analysis. ***P < 0.001.
A. Aggarwal et al. / Journal of Steroid Biochemistry & Molecular Biology 155 (2016) 231–238 233
3. Results
3.1. Effect of dietary vitamin D on proliferation, differentiation,
apoptosis and CaSR transcription in the normal colon and in tumor
xenografts
To study the anti-neoplastic functions regulated by vitamin D in
vivo, we established HT29 xenografts in mice fed with a diet
containing either low (100 IU/kg diet) or high (2500 IU/kg diet)
concentrations of vitamin D. We found no difference in tumor
volume between groups fed with low or high vitamin D (Fig.1B). As
1,25-D3 has been shown to regulate CaSR expression, we
determined CaSR expression in the tumor and colon of these
mice. While there was no difference in CaSR expression in the
tumor xenografts (Fig. 1C), the colon of mice fed with the high
vitamin D diet for 5 weeks had 2.4-fold higher CaSR expression
(P < 0.001, Fig. 1D).
The high vitamin D diet resulted in a marked decrease in the
proliferative zone of colonic crypts (deﬁned by the proliferative
marker Ki67, Fig. 2A), a 1.9-fold decrease in percentage of Ki67-
positive cells along intact crypts (P < 0.001, Fig. 2B) and a 1.6-fold
decrease in expression of the proliferation marker, cyclin D1
(Fig. 2C, P < 0.05). Expression of the intestinal differentiation
marker, alkaline phosphatase (ALP) increased 92-fold (Fig. 2D,
P < 0.001) in response to high vitamin D diet whereas sucrase
isomaltase (SI) expression was upregulated 1.5-fold (Fig. 2E,
P < 0.05). The apoptosis-deﬁning BAX/BCL-2 ratio, which measures
the balance between the pro-apoptotic and anti-apoptotic markers
was increased 1.4-fold (Fig. 2F).
3.2. Effect of 1,25-D3 on cell number in CRC cells over expressing wild
type or mutant CaSR
To study the impact of CaSR on the antiproliferative effect of
1,25-D3, stably transfected HT29 and Caco2-15 cells expressing
either the full length CaSR (CaSR-WT) or a dominant-negative
mutant receptor (CaSR-DN) were cultured for 1 week post
conﬂuence in normal medium before switching to Ca2+-free
DMEM. The cells were then treated for 48 h with 1.8 mM Ca2+, 1 nM
1,25-D3 or their combination in the presence or absence of the
positive allosteric modulator of CaSR, NPS R-568 (1 mM). Cellular
proliferation was assessed by counting viable cells using an
automated cell counter.
Treatment with 1,25-D3 had no effect on proliferation in
HT29 cells either in absence or presence of 1.8 mM Ca2+ (Fig. 3A).
However, treatment of cells with the positive allosteric modulator
of CaSR, NPS R-568, in the presence of 1.8 mM Ca2+made these cells
sensitive to the anti-proliferative effect of 1,25-D3 (Fig. 3B).
The observed anti-proliferative effect of 1,25-D3 in Caco-2 cells
was affected by the expression level of the CaSR, showing higher
potency in cells overexpressing the wild-type CaSR, but no effect in
cells carrying the mutant receptor (Fig. 3C). This effect of 1,25-D3
was further potentiated in the presence of the natural ligand (Ca2+)
(Fig. 3C) and the positive allosteric modulator NPS R-568 (Fig. 3D).
Fig. 2. Effect of dietary vitamin D on regulation of genes modulating proliferation, differentiation, and apoptosis. Expression of proliferative marker, Ki67 as assessed by
immunohistochemistry (A) and corresponding quantiﬁcation of Ki67 positive cells in intact crypts (B). Black bar represents 50 mm. We measured the mRNA expression of the
proliferation marker cyclin D1 (C), differentiation markers, ALP (D) and SI (E), and the apoptosis-deﬁning BAX/BCL2 ratio (F). Median, interquartile range and whiskers (min
and max) are shown. Statistical signiﬁcance was calculated using unpaired t-test. n = 5 animals per group. In the statistical analysis for BAX/BCL2 ratio, one signiﬁcant outlier
was identiﬁed in the low vitamin D group (using Grubbs test) and was excluded from analysis. ***P < 0.001, *P < 0.05.
234 A. Aggarwal et al. / Journal of Steroid Biochemistry & Molecular Biology 155 (2016) 231–238
3.3. Effect of 1,25-D3 on differentiation in CRC cells over expressing
wild type or mutant CaSR
Both calcium and vitamin D promote differentiation of colon
cancer cells in culture [25]. Therefore, we assessed the differenti-
ation potential of the stably transfected cells treated with 1 nM
1,25-D3 in the presence or absence of the CaSR agonists Ca2+ and
NPS R-568, for 48 h. Differentiation was measured by assessing ALP
activity.
HT29 cells have a very low differentiating potential compared
with Caco2-15 cells that are capable to differentiate spontaneously
in culture [26]. Caco2-15 cells were 10-fold more differentiated
than HT29 cells (Fig. 4). Compared with vector treated control cells,
both HT29 (Fig. 4A) and Caco2-15 cells (Fig. 4C) showed increased
ALP activity upon treatment with 1,25-D3, which was further
enhanced in the presence of a functional CaSR in HT29 cells. In
Caco2-15 cells the strong pro-differentiating effect of 1,25-D3 was
independent of the expression level of the CaSR (Fig. 4C). The
dominant negative CaSR mutant reduced the pro-differentiating
effect of 1,25-D3 both alone, and in the presence of Ca2+ (Fig. 4A and
C). Activation of the CaSR by calcium enhanced differentiation to
levels comparable to those reached by 1,25-D3 suggesting that they
work through similar molecular pathways.
To conﬁrm whether a further activation of the CaSR would affect
the pro-differentiating effect of 1,25-D3, we pre-treated the cells
with the positive allosteric CaSR modulator NPS R-568, before
treatment with 1,25-D3 and Ca2+. In HT29 cells (Fig. 4B), 1,25-D3
potentiated the effects of Ca2+ when treated with NPS R-568 and
pushed the cells to a more differentiated state. However, in Caco2-
15 cells (Fig. 4D), ALP activity was not affected signiﬁcantly upon
treatment with 1,25-D3 in the presence of NPS R-568.
3.4. Effect of 1,25-D3 on apoptosis in CRC cells overexpressing wild type
or mutant CaSR
Clinical studies as well as experimental data have shown strong
regulation of apoptosis by both Ca2+ and 1,25-D3. Therefore we
assessed the Caspase 3/7 activity in the stably transfected cells
treated with 1 nM 1,25-D3 in the presence or absence of CaSR
ligands for 48 h.
In both cell lines, Ca2+ and 1,25-D3 increased Caspase
3/7 activity compared with vector treated control cells, and this
effect was further enhanced in cells overexpressing the functional
CaSR (Fig. 5A and C). In the presence of Ca2+, 1,25-D3 was able to
further induce apoptosis in both cell lines (Fig. 5A and C). In
contrast, the dominant-negative CaSR inhibited Caspase
3/7 activity, suggesting that the CaSR has an important role in
regulating apoptosis (Fig. 5).
To conﬁrm whether a further activation of the CaSR would affect
the pro-apoptotic effects of 1,25-D3, we pre-treated the cells with
the positive allosteric CaSR modulator NPS R-568, before treatment
with 1,25-D3. Both in HT29 (Fig. 5B) and Caco2-15 cells (Fig. 5D),
apoptosis was signiﬁcantly higher in cells overexpressing the wild-
type CaSR. The activation of the CaSR by its allosteric modulator
Fig. 3. Impact of CaSR on the anti-proliferative effects of 1,25-D3. Proliferation was measured by counting viable cells in stably transfected HT29 (A and B) and Caco2-15 cells
(C and D). White bars represent cells transfected with the EMPTY vector, grey bars represent cells transfected with the WT CaSR and black bars represent the cells transfected
with the DN CaSR. Bars represent mean  SEM. Statistical signiﬁcance was calculated using two-way ANOVA followed by Tukey’s correction. Hashtags above bars denote
signiﬁcant changes within groups (compared with EMPTY cells), #P < 0.05, ##P < 0.01, ###P < 0.001. F indicates signiﬁcant changes between control group and treatment
group for respective genotype, FP < 0.05, FFP < 0.01, FFFP < 0.001. Asterisks above bars indicate signiﬁcant changes between single agent and combined treatment groups,
*P < 0.05, **P < 0.01, ***P < 0.001.
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further sensitized the cells to the pro-apoptotic effect of 1,25-D3. In
the presence of the non-functional CaSR mutant these effects were
diminished.
4. Discussion
There is increasing evidence that calcium and vitamin D can
modify, prevent or even abrogate colorectal tumor development. In
the present study we show that a high vitamin D diet reduced
proliferation, increased differentiation and apoptosis, and in
parallel, upregulated mRNA expression of the calcium-sensing
receptor in the colon of mice. By applying a mechanistic model we
demonstrate that the CaSR is a link for a direct cross talk between
calcium and vitamin D signaling in the colon that facilitates 1,25-
D3-mediated anti-neoplastic effects. We show for the ﬁrst time
that expression level as well as functionality of the CaSR affects the
cancer preventive action of the active vitamin D3: the higher the
expression level or activity of the CaSR, the stronger the effect of
1,25-D3.
We have previously reported that increasing dietary Ca2+ led to
signiﬁcant downregulation of the vitamin D degrading enzyme,
1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1) in the colon
of mice [7]. Low calcium in the diet of mice led to hyper-
proliferative and hypo-apoptotic colonic crypts [7,8]. In the present
in vivo study, mice fed with the high vitamin D diet exhibited
signiﬁcantly higher CaSR expression, fewer proliferating cells, and
showed in general, downregulation of colonic proliferation and
upregulation of differentiation and apoptosis in the normal colon
(Figs. 1 and 2). This led us to hypothesize that the CaSR could be a
molecular link supporting the cross talk between calcium signaling
and the vitamin D system, thereby increasing the effectiveness of
these compounds as combinational chemopreventive agents in the
colon.
To test this hypothesis, we transfected HT29 and Caco2-15 cells
with either a full-length wild type CaSR construct, or an
inactivating mutant (R185Q). We saw that the anti-neoplastic
effects of 1,25-D3 were dependent on both the amount and
functionality of the CaSR. These results were conﬁrmed by treating
cells with NPS R-568, a positive allosteric modulator that increases
the sensitivity of the CaSR to calcium [27]. Only the
pro-differentiating effect of 1,25-D3 in the Caco-2 cells seem to
be independent of the exogenous CaSR activation. 1,25-D3 is a
strong inducer of differentiation of these cells. Such a high
differentiation was reached with Ca2+ only if the CaSR was either
overexpressed or further activated by the allosteric modulator.
Whether calcium and 1,25-D3 induce differentiation through the
same mechanisms needs to be determined. Strikingly, in both cell
lines, the anti-proliferative, pro-differentiating, and pro-apoptotic
functions of 1,25-D3 were reduced in the presence of the
dominant-negative mutant of the CaSR. This suggests that the
anti-neoplastic effects of 1,25-D3 are, at least in part, inﬂuenced by
the CaSR.
It is not surprising that the anti-neoplastic effects of Ca2+ are
CaSR dependent, given that Ca2+ is one of the physiological ligands
of CaSR. It was previously shown that CaSR gene promoters are
functionally responsive to both Ca2+ and 1,25-D3 and that a
Fig. 4. Impact of CaSR on the pro-differentiating effects of 1,25-D3. Differentiation was assessed by measuring ALP activity in stably transfected HT29 (A and B) and Caco2-
15 cells (C and D). White bars represent cells transfected with the EMPTY vector, grey bars represent cells transfected with the WT CaSR and black bars represent the cells
transfected with the DN CaSR. Bars represent mean  SEM. Statistical signiﬁcance was calculated using two-way ANOVA followed by Tukey’s correction. Hashtags above bars
denote signiﬁcant changes within groups (compared with EMPTY cells), #P < 0.05, ##P < 0.01, ###P < 0.001. F indicates signiﬁcant changes between control group and
treatment group for respective genotype, FP < 0.05, FFP < 0.01, FFFP < 0.001. Asterisks above bars indicate signiﬁcant changes between single agent and combined
treatment groups, *P < 0.05, **P < 0.01, ***P < 0.001.
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combination of these agents enhances CaSR promoter activity in
the colon [15]. 1,25-D3 can bind to the VDRE in the promoter of the
CaSR gene, and regulate its expression [13]. Interestingly, 1,25-D3
was not able to enhance CaSR expression in HT29 cells (data not
shown), probably due to the high methylation level of the second
CaSR promoter region, which harbors the VDRE [20]. This might
explain why in the xenografts the high vitamin D diet had no effect
on CaSR expression.
It is however, surprising that the presence of the CaSR-DN
mutant restricts the anti-neoplastic functions of 1,25-D3. The
inactivating R185Q mutant of the CaSR is able to dimerize with
endogenous CaSR and reduces the functionality of the latter [28].
We speculate that the CaSR-DN interferes with or even negatively
modulates gene expression of molecules that may be downstream
of the vitamin D signaling pathway, thereby suppressing the
functions directly mediated by 1,25-D3.
Recently, Ahearn et al. [29] in a randomized, double blinded
study showed that colorectal adenoma patients supplemented
with calcium had lower CYP24A1 expression in the normal colonic
tissue. In the same study, patients supplemented with vitamin D
showed upregulation of colonic CaSR expression. Considering that
CaSR expression was upregulated by vitamin D also in our in vivo
model, taken together with our previous ﬁndings that vitamin D
system genes can be regulated by calcium in vivo [7], we suggest
the existence of a cross talk between calcium signaling and the
vitamin D system to protect the colon from neoplastic transfor-
mation. In this cross talk, the CaSR seems to play a central role. Liu
et al. have also shown that vitamin D promotes its growth-
inhibitory actions in a CaSR-dependent manner [30]. This is further
evidenced in our in vitro study where the inactivating mutation of
the CaSR interferes with 1,25-D3-mediated anti-tumorigenic
processes. Given that colonic cells acquire CaSR expression as
they migrate to the crypt apex [15,20] where a balance between
apoptosis and differentiation is tightly regulated, it seems
plausible that loss of the CaSR during colorectal tumorigenesis
confers transformed cells resistance to calcium and vitamin
D-mediated growth regulation.
In order to understand the effect of calcium and vitamin D in
combinational chemoprevention, there is a need to elucidate the
mechanisms that support their interplay at the molecular level. In
this study we showed that the expression level and functionality of
the CaSR alters 1,25-D3-mediated signaling. Since CaSR expression
is lost during colorectal tumorigenesis, this might be a further
explanation for the low responsiveness of colonic tumors to 1,25-
D3. Our data suggest that the CaSR might become a possible target
in colon cancer therapy. We have recently shown that hyper-
methylation and deacetylation of the CaSR promoter are responsi-
ble, at least in part, for silencing of CaSR expression in colorectal
tumors [20]. Development of agents that can induce CaSR
expression, and the elucidation of signaling pathways by which
Fig. 5. Impact of CaSR on the pro-apoptotic effects of 1,25-D3. Apoptosis was assessed by measuring Caspase 3/7 activity in stably transfected HT29 (A and B) and Caco2-
15 cells (C and D). White bars represent cells transfected with the EMPTY vector, grey bars represent cells transfected with the WT CaSR and black bars represent the cells
transfected with the DN CaSR. Bars represent mean  SEM. Statistical signiﬁcance was calculated using two-way ANOVA followed by Tukey’s correction. Hashtags above bars
denote signiﬁcant changes within groups (compared with EMPTY cells), #P < 0.05, ##P < 0.01, ###P < 0.001. F indicates signiﬁcant changes between control group and
treatment group for respective genotype, FP < 0.05, FFP < 0.01, FFFP < 0.001. Asterisks above bars indicate signiﬁcant changes between single agent and combined
treatment groups, *P < 0.05, **P < 0.01, ***P < 0.001.
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1,25-D3 and CaSR cooperate for preventing malignant transforma-
tion in the colon could help in improving outcome in patients.
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